“Efficacy and Safety of the Melanocortin-4 Receptor Agonist Setmelanotide in Obesity Due to Bardet-Biedl Syndrome: a Phase 3 Trial Phase 3 Trial of Setmelanotide in Bardet-Biedl Syndrome”
Robert Haws, M.D., Clinical Research Center at the Marshfield Clinic Research Institute
Poster
“Setmelanotide in POMC, PCSK1, or LEPR Heterozygous Deficiency Obesity (Phase 2)”
Sadaf Farooqi, PhD, Wellcome-MRC Institute of Metabolic Science and NIHR Cambridge Biomedical Research Centre, University of Cambridge, Cambridge, UK
Poster
“Variants in Obesity-related Genes in a Population with Early-onset Obesity”
Patrick Kleyn, Ph.D., Vice President, Translational R&D, Rhythm Pharmaceuticals
Poster
“Trial of a Once-weekly Setmelanotide Formulation in Patients with Obesity”
Annette Valles-Sukkar, MHP, CCRA, MT(ASCP), Director Clinical Operations, Rhythm Pharmaceuticals
Poster
“Quality of Life in POMC or LEPR Deficiency: Setmelanotide Phase 3 Trials”
Peter Kühnen, MD, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin und Humboldt-Universität zu Berlin, Institute for Experimental Pediatric Endocrinology, Berlin, Germany
Poster
“Patient Experience of Hunger in POMC or LEPR Deficiency”
Martin Wabitsch, Division of Pediatric Endocrinology and Diabetes, Center for Rare Endocrine Diseases, Department of Pediatrics and Adolescent Medicine, University of Ulm, Ulm, Germany
Poster
“Frequency of BBS and AS Gene Variants in a Cohort with Early-onset Obesity”
Joan Han, MD, Director of the Pediatric Obesity Program at Le Bonheur Children’s Hospital, Associate Professor, Division of Pediatric Endocrinology at the University of Tennessee Health Science Center
Poster
Rhythm Pharmaceuticals, Inc.
222 Berkeley Street, 12th Floor
Boston, MA 02116